Program
zeprumetostat
Also written as “SHR2554”, “TLN-254” and “SHR2554 Tablets”.
Its studies are mostly in Lymphoma · Neoplasms · Prostatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms, led by 2 companies.
Drug pageZeprumetostat: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicineits history only | 166 open or running | phase 3since Nov 5, 2023 | Jul 10, 2018 | Apr 2027phase 2 · NCT06368167 |
| Treeline Biosciencesits history only | 11 open or running | phase 1since Dec 10, 2024 | Dec 10, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Jul 10, 2018.
- Sep 24, 2020Phase 1 study in HealthyJiangsu HengRui Medicine · NCT04577885 · 18 enrolled · China
- Oct 27, 2020Phase 1 study in Healthy Adult SubjectsJiangsu HengRui Medicine · NCT04627129 · 18 enrolled · China
- Sep 9, 2021Phase 1 study in LymphomaJiangsu HengRui Medicine · NCT05049083 · 28 enrolled · China
- Oct 20, 2022Phase 1 study in NeoplasmsJiangsu HengRui Medicine · NCT05592262 · 20 enrolled · China
- Dec 15, 2022Phase 1 study in NeoplasmsJiangsu HengRui Medicine · NCT05661591 · 18 enrolled · China
- Aug 20, 2023Phase 1 study in LymphomaJiangsu HengRui Medicine · NCT06010680 · 6 enrolled · China
- Oct 17, 2023Phase 1 study in NeoplasmsJiangsu HengRui Medicine · NCT06093945 · 20 enrolled · China
- Nov 5, 2023Phase 3 study in RecurrenceJiangsu HengRui Medicine · NCT06122389 · 130 planned · China
- Dec 8, 2023Phase 2 study in Lymphoma, T-Cell, PeripheralJiangsu HengRui Medicine · NCT06173999 · 100 planned · China
- Apr 11, 2024Phase 2 study in Lymphoma, FollicularJiangsu HengRui Medicine · NCT06368167 · 105 planned · China
- Aug 11, 2024Named zeprumetostatINNProposed as its International Nonproprietary Name in WHO's List 131 · before, SHR2554, TLN-254
- Dec 10, 2024Treeline Biosciences’ first study: phase 1 study in LymphomaNew to Treeline BiosciencesTreeline Biosciences · NCT06733441 · 50 enrolled · United States, Canada
- Jul 29, 2025Phase 2 study in Stomach NeoplasmsJiangsu HengRui Medicine · NCT07102901 · 351 planned · China
- Sep 9, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungJiangsu HengRui Medicine · NCT07175220 · 200 planned · China
- Nov 13, 2025Phase 2 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT07230106 · 218 planned · China
Ahead
- Nov 15, 2026Primary completion: phase 1 study in LymphomaTreeline Biosciences · NCT06733441
- Apr 2027Primary completion: phase 2 study in Lymphoma, FollicularJiangsu HengRui Medicine · NCT06368167
- Dec 2027Primary completion: phase 2 study in Stomach NeoplasmsJiangsu HengRui Medicine · NCT07102901
- Oct 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungJiangsu HengRui Medicine · NCT07175220
TargetBeta
“An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), ”NCIt, by rule
Other programs on EZH2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mevrometostat | Pfizer | phase 3 | 7 |
| TR115rule | tarapeutics-science-inc | phase 3 | 3 |
| tulmimetostat | Novartis | phase 2 | 3 |
| EZH1/2 Inhibitor HH2853rule | Haihe Biopharma | phase 2 | 2 |
| valemetostatrule | Daiichi Sankyo | phase 1 | 1 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07230106Prostatic Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2028 | 218 |
| NCT07175220Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Jiangsu HengRui Medicine | Oct 2028 | 200 |
| NCT07102901Stomach Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2027 | 351 |
| NCT06733441Lymphoma · United States, Canada | 1 | Active, not recruiting | Treeline Biosciences | Nov 15, 2026 | 50 |
| NCT06368167Lymphoma, Follicular · China | 2 | Not yet recruiting | Jiangsu HengRui Medicine | Apr 2027 | 105 |
| NCT06173999Lymphoma, T-Cell, Peripheral · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 31, 2025 | 100 |
| NCT06122389Recurrence · China | 3 | Recruiting | Jiangsu HengRui Medicine | May 2026 | 130 |
| NCT06093945Neoplasms · China | 1 | Completed | Jiangsu HengRui Medicine | Nov 29, 2023 | 20 |
| NCT06010680Lymphoma · China | 1 | Completed | Jiangsu HengRui Medicine | Nov 27, 2023 | 6 |
| NCT05661591Neoplasms · China | 1 | Completed | Jiangsu HengRui Medicine | Mar 31, 2023 | 18 |
| NCT05592262Neoplasms · China | 1 | Completed | Jiangsu HengRui Medicine | Dec 14, 2022 | 20 |
| NCT05049083Lymphoma · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Jan 6, 2022 | 28 |
| NCT04627129Healthy Adult Subjects · China | 1 | Completed | Jiangsu HengRui Medicine | Oct 1, 2020 | 18 |
| NCT04577885Healthy · China | 1 | Completed | Jiangsu HengRui Medicine | Aug 30, 2020 | 18 |
| NCT04335266Healthy Adult Subjects · China | 1 | Completed | Jiangsu HengRui Medicine | Sep 9, 2019 | 20 |
| NCT03741712Prostatic Neoplasms · China | 2 | Terminated | Jiangsu HengRui Medicine | Sep 30, 2019 | 9 |
| NCT03603951Recurrence · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Feb 14, 2026 | 272 |
How it is read
Names in the registry
- “SHR2554”, 6 entries
- “TLN-254”, 2 entries
- “SHR2554 Tablets”, 2 entries
- “SHR2554 Tablet”, 1 entry
- “SHR2554; Chidamide analog tablets”, 1 entry
Codes read as this program: SHR2554.
Conditions, from the studies’ own filings
- Lymphoma, 3 studies
- Neoplasms, 3 studies
- Prostatic Neoplasms, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.